AUP.TO
Price:
$16.76
Market Cap:
$0
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.[Read more]
Industry
Medical - Specialties
IPO Date
2000-09-19
Stock Exchange
TSX
Ticker
AUP.TO
According to Aurinia Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -11.45. This represents a change of -3.43% compared to the average of -11.85 of the last 4 quarters.
The mean historical PE Ratio of Aurinia Pharmaceuticals Inc. over the last ten years is -18.63. The current -11.45 PE Ratio has changed 6.04% with respect to the historical average. Over the past ten years (40 quarters), AUP.TO's PE Ratio was at its highest in in the December 2013 quarter at 309.51. The PE Ratio was at its lowest in in the June 2015 quarter at -146.39.
Average
-18.63
Median
-17.54
Minimum
-39.21
Maximum
-6.15
Discovering the peaks and valleys of Aurinia Pharmaceuticals Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 537.37%
Maximum Annual PE Ratio = -6.15
Minimum Annual Increase = -73.93%
Minimum Annual PE Ratio = -39.21
Year | PE Ratio | Change |
---|---|---|
2020 | -11.92 | 23.07% |
2019 | -9.69 | -40.34% |
2018 | -16.24 | 11.89% |
2017 | -14.51 | -22.95% |
2016 | -18.84 | -10.00% |
2015 | -20.93 | -17.08% |
2014 | -25.24 | -35.63% |
2013 | -39.21 | 537.37% |
2012 | -6.15 | -73.93% |
2011 | -23.60 | 86.63% |
The current PE Ratio of Aurinia Pharmaceuticals Inc. (AUP.TO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-12.62
5-year avg
-14.24
10-year avg
-18.63
Aurinia Pharmaceuticals Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aurinia Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aurinia Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aurinia Pharmaceuticals Inc.'s PE Ratio?
How is the PE Ratio calculated for Aurinia Pharmaceuticals Inc. (AUP.TO)?
What is the highest PE Ratio for Aurinia Pharmaceuticals Inc. (AUP.TO)?
What is the 3-year average PE Ratio for Aurinia Pharmaceuticals Inc. (AUP.TO)?
What is the 5-year average PE Ratio for Aurinia Pharmaceuticals Inc. (AUP.TO)?
How does the current PE Ratio for Aurinia Pharmaceuticals Inc. (AUP.TO) compare to its historical average?